NCT05019690View on ClinicalTrials.gov

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

June 1, 2025

Conditions
Advanced Triple Negative Breast Cancer
Interventions
DRUG

Apatinib Mesylate

Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W

DRUG

Albumin-Bound Paclitaxel

Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W

Trial Locations (1)

Unknown

RECRUITING

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV